Laboratorios Farmaceuticos Rovi SA (CHIX:ROVIe)

Q2 2026 Laboratorios Farmaceuticos ROVI SA Earnings Call Transcript

Jul 23, 2026 / 08:00 AM GMT

Release Date Price: €62.6

Transcript

Key Points

Positve

Total revenue increased by 13% to EUR 357 million in the first half of 2026.
Operating revenue grew by 9% to EUR 344.2 million, driven by a 38% increase in the CDMO business.
Gross profit rose by 21% to EUR 237.1 million, with a gross margin improvement of 6.5 percentage points.
Successful acquisition of the Phoenix manufacturing facility in Arizona, strengthening the company's industrial footprint in the U.S.
Strong cash generation with free cash flow increasing significantly to EUR 64.7 million, highlighting the company's ability to convert earnings into cash.

Negative

Sales of the heparin franchise declined by 4% year-over-year, with low molecular weight heparin sales down 5%.
EBITDA, excluding the impact of bad will, decreased by 10% to EUR 58.8 million.
SG&A expenses increased by 28% to EUR 145 million, driven by personnel costs and non-recurring expenses.
R&D expenses surged by 98% to EUR 33.3 million, impacting overall profitability.
The company faces ongoing pricing pressure in the heparin sector, necessitating efficiency initiatives to mitigate impact.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ROVI.MC - Laboratorios Farmaceuticos ROVI SA
Q2 2026 Laboratorios Farmaceuticos ROVI SA Earnings Call
Jul 23, 2026 / 08:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello, everyone. This is Marta Campos, Head of Finance for Rovi.

Welcome to our company's review of business results for the first half of 2026.

Before we begin, let me remind you that today's presentation and associated documentation are available on the Investor Relations section of Rovi's website.

Please note that the information presented in this call contains forward-looking statements based on our current beliefs and expectations.

Actual results could naturally differ due to known and unknown risks, uncertainties, and other factors, and we undertake no obligation to update or revise any of the statements.

Moving to today's agenda.

Juan Lopez

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.